← Leaderboards
Robert C Seeger
University Of Southern California
$12,536,093
Attributed
$13,556,913
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$48,581,678 · 17
By mechanism
P01$39,055,008 · 10
R01$7,536,457 · 3
R33$1,296,051 · 1
M01$694,162 · 2
P30$0 · 1
Top collaborators
- Shahab Asgharzadeh3 shared
- John M Maris3 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Timothy J. Triche$21,258,785
- Hossein Jadvar$3,348,579
- Smita Bhatia$27,398,641
- Jonathan Buckley$2,690,403
- Judith Villablanca$191,317
Others in their field
Top investigators on “Neuroblastoma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Gregory H Reaman · National Childhood Cancer Foundation$84,462,747
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$58,436,699
- Larry Arthur$30,516,306
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
NeuroblastomaClinical TrialsHigh RiskNeoplastic CellBaseTumorGene ExpressionSiteResearch DesignHuman SubjectChildChemotherapyCellsCell LineClinical ResearchResistanceAutologousHuman Therapy EvaluationAccountingCollaborationsMalignant NeoplasmsSpecimenBone MarrowImmunotherapy
Grant awards (83)
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,078,428
P01 · FY2019 · CA · contact PI
Enhancing the Potency and Durability of Immunotherapies$498,946
P01 · FY2019 · CA · contact PI
Biostatics$141,891
P01 · FY2019 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,171,238
P01 · FY2018 · CA · contact PI
Enhancing the Potency and Durability of Immunotherapies$521,774
P01 · FY2018 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,296,936
P01 · FY2017 · CA · contact PI
Enhancing the Potency and Durability of Immunotherapies$328,134
P01 · FY2017 · CA · contact PI
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma$665,155
R01 · FY2016 · CA
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma$671,686
R01 · FY2015 · CA
Biology and Therapy of High Risk Neuroblastoma$1,925,523
P01 · FY2014 · CA · contact PI
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma$704,800
R01 · FY2014 · CA
NATURAL KILLER CELL BASED IMMUNOTHERAPY$182,034
P01 · FY2014 · CA · contact PI
RESEARCH SUPPORT SERVICES$29,450
P01 · FY2014 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$1,876,546
P01 · FY2013 · CA · contact PI
NATURAL KILLER CELL BASED IMMUNOTHERAPY$181,860
P01 · FY2013 · CA · contact PI
RESEARCH SUPPORT SERVICES$163,631
P01 · FY2013 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$2,006,380
P01 · FY2012 · CA · contact PI
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome$426,711
R33 · FY2012 · CA · contact PI
NATURAL KILLER CELL BASED IMMUNOTHERAPY$189,217
P01 · FY2012 · CA · contact PI
RESEARCH SUPPORT SERVICES$35,327
P01 · FY2012 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$2,015,534
P01 · FY2011 · CA · contact PI
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome$427,618
R33 · FY2011 · CA · contact PI
NATURAL KILLER CELL BASED IMMUNOTHERAPY$190,425
P01 · FY2011 · CA · contact PI
RESEARCH SUPPORT SERVICES$35,940
P01 · FY2011 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$2,135,965
P01 · FY2010 · CA · contact PI
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome$441,722
R33 · FY2010 · CA · contact PI
Clinical Correlative Studies of Neuroblastoma$428,770
R01 · FY2010 · CA · contact PI
NATURAL KILLER CELL BASED IMMUNOTHERAPY$196,933
P01 · FY2010 · CA · contact PI
RESEARCH SUPPORT SERVICES$37,364
P01 · FY2010 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$1,950,665
P01 · FY2009 · CA · contact PI
Clinical Correlative Studies of Neuroblastoma$421,986
R01 · FY2009 · CA · contact PI
Clinical Correlative Studies of Neuroblastoma$397,563
R01 · FY2009 · CA · contact PI
IMMUNOTHERAPY$284,699
P01 · FY2009 · CA · contact PI
RESEARCH SUPPORT SERVICES$52,188
P01 · FY2009 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$1,908,071
P01 · FY2008 · CA · contact PI
Clinical Correlative Studies of Neuroblastoma$411,318
R01 · FY2008 · CA · contact PI
IMMUNOTHERAPY$209,809
P01 · FY2008 · CA · contact PI
RESEARCH SUPPORT SERVICES$38,828
P01 · FY2008 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$1,899,503
P01 · FY2007 · CA · contact PI
Clinical Correlative Studies of Neuroblastoma$408,898
R01 · FY2007 · CA · contact PI
IMMUNOTHERAPY$204,810
P01 · FY2007 · CA · contact PI
RESEARCH SUPPORT SERVICES$38,271
P01 · FY2007 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$1,909,108
P01 · FY2006 · CA · contact PI
Clinical Correlative Studies of Neuroblastoma$468,286
R01 · FY2006 · CA · contact PI
IMMUNOTHERAPY$199,954
P01 · FY2006 · CA · contact PI
RESEARCH SUPPORT SERVICES$37,730
P01 · FY2006 · CA · contact PI
Biology and Therapy of High Risk Neuroblastoma$1,938,669
P01 · FY2005 · CA
Clinical Correlative Studies of Neuroblastoma$467,554
R01 · FY2005 · CA
IMMUNOTHERAPY$194,308
P01 · FY2005 · CA
RESEARCH SUPPORT SERVICES$36,720
P01 · FY2005 · CA
BIOLOGY AND THERAPY OF HIGH-RISK NEUROBLASTOMA$1,819,507
P01 · FY2004 · CA
Clinical Correlative Studies of Neuroblastoma$457,850
R01 · FY2004 · CA
BIOLOGY AND THERAPY OF HIGH-RISK NEUROBLASTOMA$1,775,574
P01 · FY2003 · CA
Clinical Correlative Studies of Neuroblastoma$455,319
R01 · FY2003 · CA
BIOLOGY AND THERAPY OF HIGH-RISK NEUROBLASTOMA$10,416
P01 · FY2003 · CA
BIOLOGY AND THERAPY OF HIGH-RISK NEUROBLASTOMA$1,768,480
P01 · FY2002 · CA
Clinical Correlative Studies of Neuroblastoma$467,430
R01 · FY2002 · CA
Core--Research support services$0
P01 · FY2002 · CA
PHASE I STUDY--CHIMERIC HUMAN /MURINE ANTI-GD2 MAB WITH BM-CSF IN NEUROBLASTOMA$0
M01 · FY2002 · RR
PHASE 1 STUDY OF HUMAN GAMMA INTERFERON GENE-TRANSDUCED TUMOR CELLS$0
M01 · FY2002 · RR
PILOT--DEVELOPMENTAL THERAPEUTICS AND CLINICAL TRIALS$0
P30 · FY2002 · CA
Immunocytokine therapy$0
P01 · FY2002 · CA
PILOT--DEVELOPMENTAL THERAPEUTICS AND CLINICAL TRIALS$0
P30 · FY2002 · CA
BIOLOGY AND THERAPY OF HIGH-RISK NEUROBLASTOMA$1,737,898
P01 · FY2001 · CA
CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA$420,741
R01 · FY2001 · CA
PHASE 1 STUDY OF HUMAN GAMMA INTERFERON GENE-TRANSDUCED TUMOR CELLS$155,764
M01 · FY2001 · RR
PHASE I STUDY--CHIMERIC HUMAN /MURINE ANTI-GD2 MAB WITH BM-CSF IN NEUROBLASTOMA$155,764
M01 · FY2001 · RR
PHASE I STUDY--CHIMERIC HUMAN /MURINE ANTI-GD2 MAB WITH BM-CSF IN NEUROBLASTOMA$0
M01 · FY2001 · RR
PILOT--DEVELOPMENTAL THERAPEUTICS AND CLINICAL TRIALS$0
P30 · FY2001 · CA
PILOT--DEVELOPMENTAL THERAPEUTICS AND CLINICAL TRIALS$0
P30 · FY2001 · CA
Core--Research support services$0
P01 · FY2001 · CA
Immunocytokine therapy$0
P01 · FY2001 · CA
PHASE 1 STUDY OF HUMAN GAMMA INTERFERON GENE-TRANSDUCED TUMOR CELLS$0
M01 · FY2001 · RR
BIOLOGY AND THERAPY OF HIGH-RISK NEUROBLASTOMA$1,800,324
P01 · FY2000 · CA
CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA$413,515
R01 · FY2000 · CA
HUMAN NEUROBLASTOMA ANTIGENS$238,455
R01 · FY2000 · CA
PHASE 1 STUDY OF HUMAN GAMMA INTERFERON GENE-TRANSDUCED TUMOR CELLS$155,764
M01 · FY2000 · RR
PHASE I STUDY--CHIMERIC HUMAN /MURINE ANTI-GD2 MAB WITH BM-CSF IN NEUROBLASTOMA$155,764
M01 · FY2000 · RR
CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA$37,131
R01 · FY2000 · CA
PHASE 1 STUDY OF HUMAN GAMMA INTERFERON GENE-TRANSDUCED TUMOR CELLS$35,553
M01 · FY2000 · RR
PHASE I STUDY--CHIMERIC HUMAN /MURINE ANTI-GD2 MAB WITH BM-CSF IN NEUROBLASTOMA$35,553
M01 · FY2000 · RR
Core--Research support services$0
P01 · FY2000 · CA
Immunocytokine therapy$0
P01 · FY2000 · CA